Advertisement
open access
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2022 Medicom Conference Planning
  • Conference Proceedings
  • Disease Areas
  • Other Medical News
  • Podcast
  • Videos
  • Education
  • About
    • Vacancies

Tag: Atopic Dermatitis

AD treatment during the pandemic: dupilumab does not raise COVID-19 infection risk

Presented By
Dr Brian Rankin, University of Calgary, Canada
Trial
Cohort study
Conference
AAD 2022

18 May, 2022 12:27

Upadacitinib: Fast and more pronounced skin improvement in AD patients

Presented By
Prof. Jonathan Silverberg, George Washington University School of Medicine, USA
Trial
Phase 3, Heads Up
Conference
AAD 2022

17 May, 2022 12:35

Lebrikizumab treatment leads to encouraging outcomes in multiple traits of AD

Presented By
Prof. Jonathan Silverberg, George Washington University School of Medicine, USA
Trial
Phase 3, ADvocate1; ADvocate2
Conference
AAD 2022

17 May, 2022 12:18

Novel IL-4/IL-13 blocker shows high efficacy with only modest conjunctivitis signal

Presented By
Prof. Andrew Blauvelt, Oregon Medical Research Center, USA
Conference
AAD 2022

17 May, 2022 12:15

JAK inhibitors: A risk assessment

Presented By
Prof. Brett King, Yale School of Medicine, USA
Conference
AAD 2022

17 May, 2022 10:59

Monitoring is key during JAK inhibitor therapy

Presented By
Prof. Jonathan Silverberg
Conference
AAD 2022

17 May, 2022 10:47

AAD 2022 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
AAD 2022

14 April, 2022 11:02

Ceramides and their role in skincare

Presented By
Prof. John Su; Dr Katherine Armour
Conference
ICD 2021

2 December, 2021 16:47

Targeting OX40 in the treatment of atopic dermatitis meets expectations

Presented By
Prof. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany
Trial
Phase 2
Conference
EADV 2021

18 November, 2021 13:35

Superior EASI scores after switch from dupilumab to upadacitinib

Presented By
Prof. Andrew Blauvelt, Oregon Medical Research Center, USA
Trial
Heads Up
Conference
EADV 2021

18 November, 2021 13:34

Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083

Presented By
Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA
Trial
Phase 2
Conference
EADV 2021

18 November, 2021 13:28

Abrocitinib demonstrates fast itch control and skin clearance in atopic dermatitis

Presented By
Prof. Kristian Reich, University Medical Center Hamburg-Eppendorf, Germany
Trial
Phase 3, JADE DARE
Conference
EADV 2021

18 November, 2021 13:26

AD patients with stable response fare well with a monthly dose of tralokinumab

Presented By
Prof. Stephan Weidinger, University of Kiel, Germany
Trial
ECZTRA1 and 2
Conference
EADV 2021

18 November, 2021 13:25

Upadacitinib beats dupilumab in different body regions

Presented By
Prof. Jacob Thyssen, Bispebjerg Hospital, Denmark
Trial
Phase 3, Heads Up
Conference
EADV 2021

18 November, 2021 13:23

Efficacious 2-year AD control with IL-13 inhibitor tralokinumab

Presented By
Prof. Andrew Blauvelt, Oregon Medical Research Center, USA
Trial
ECZTEND
Conference
EADV 2021

18 November, 2021 13:22

Ruxolitinib cream: a safe treatment for elderly AD patients

Presented By
Prof. Jacek Szepietowksi, Wroclaw Medical University, Poland
Trial
Phase 3, TRuE-AD1; TRuE-AD2
Conference
11:00:48pm> from conference

18 November, 2021 13:21

Novel and upcoming targeted AD treatment

Presented By
Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA
Trial
ECZTRA 3; Measure Up; ADVISE
Conference
EADV 2021

18 November, 2021 13:20

Opioid receptor agonist difelikefalin disappoints in AD

Presented By
Prof. Brian Kim, Washington University School of Medicine, USA
Trial
Phase 2, KARE
Conference
EADV 2021

17 November, 2021 14:28

EADV 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Trial
PSOARING 3, JADE-DARE, HEADS UP
Conference
EADV 2021

19 October, 2021 00:08

Meaningful sleep improvement with IL-13 inhibition

Presented By
Prof. Jonathan Silverberg, George Washington University, USA
Trial
Phase 3, ECZTRA
Conference
EADV 2020

17 December, 2020 14:33

Baricitinib in AD: Efficacy paired with consistent long-term results

Presented By
Prof. Jonathan Silverberg , George Washington University, USA
Trial
Phase 3, BREEZE-AD3
Conference
EADV 2020

17 December, 2020 14:31

Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD

Presented By
Prof. Megan Landis, University of Louisville School of Medicine, USA
Trial
Phase 2
Conference
EADV 2020

17 December, 2020 14:22

Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD

Presented By
Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA
Trial
Phase 3, Measure Up
Conference
EADV 2020

17 December, 2020 13:24

Effects IL-13 blocker improves with longer treatment duration

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
Trial
Phase 3, ECZTRA
Conference
EADV 2020

17 December, 2020 12:37

Baricitinib beneficial in head and neck AD

Presented By
Dr Eric Simpson, Oregon Health and Science University, USA
Trial
Phase 3, BREEZE-AD1 and BREEZE-AD2
Conference
AAD 2020

19 August, 2020 07:23

Cannabinoids: a future role in dermatology?

Presented By
Prof. Adam Friedman, School of Medicine & Health Sciences, USA
Conference
AAD 2020

6 August, 2020 09:01

Good response and pruritus reduction in AD with novel selective JAK1 inhibitor

Presented By
Dr Melinda Gooderham
Trial
JADE MONO-2
Conference
AAD 2020

6 August, 2020 07:08

IL-13 blocker tralokinumab effective in AD

Presented By
Prof. Eric Simpson
Trial
ECZTRA
Conference
AAD 2020

6 August, 2020 07:06

Tape stripping – a painless way to distinguish AD and psoriasis?

Presented By
Dr Robert Bissonnette, Innovaderm Research, Canada
Conference
AAD 2020

6 August, 2020 07:05

IL-4/IL-13 blocker dupilumab effective in children with severe AD

Presented By
Prof. Amy S. Paller, Northwestern University Feinberg School of Medicine, USA
Trial
Phase 3, LIBERTY AD PEDS
Conference
AAD 2020

6 August, 2020 07:04

Better compliance in AD skin care with novel emollient stick

Conference
AAD 2020

6 August, 2020 06:37

Small molecules: interesting novel treatment options in AD

Presented By
Prof. Tilo Biedermann, Helmholtz Center Munich, German
Conference
EADV 2019

9 December, 2019 20:27

IL-1⍺ blockade: a new treatment option in AD

Presented By
Prof. Alice Gottlieb, Icahn School of Medicine at Mount Sinai, USA
Conference
EADV 2019

9 December, 2019 19:51

IL-4/IL-13 blockade leads to rapid itch reduction in adolescents

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
Trial
Phase 3, LIBERTY AD ADOL
Conference
EADV 2019

9 December, 2019 18:58

JAK inhibition plus TCS lead to high clearance rates in AD

Presented By
Prof. Kristian Reich, Georg-August-University Göttingen, Germany
Trial
Phase 3, BREEZE-AD7

9 December, 2019 16:53

How to manage conjunctivitis in AD patients treated with a biologic

Presented By
Prof. Tilo Biedermann, Helmholtz Center Munich, Germany
Conference
EADV 2019

9 December, 2019 16:01

Biologics: increasingly used in paediatric dermatology

Presented By
Prof. Marieke Seyger, Radboud University Nijmegen, the Netherlands
Conference
EADV 2019

9 December, 2019 15:16

No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD

Presented By
Prof. Regina Fölster-Holst, University Medical Center Schleswig-Holstein, Germany
Trial
APPLES
Conference
EADV 2019

9 December, 2019 15:04

Green light for a second JAK inhibitor in AD

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
Trial
Phase 3, JADE MONO-1
Conference
EADV 2019

9 December, 2019 14:06

Comorbidities more common in chronic urticaria, psoriasis, and AD

Presented By
Dr Karsten Weller, Charité University Hospital, Germany
Conference
EADV 2019

9 October, 2019 20:40

Reduced sleep quality in dermatoses influenced by itch and pain

Presented By
Dr Karolina Kaaz, Wroclaw Medical University, Poland
Conference
EADV 2019

9 October, 2019 19:58

Anxiety and depression are common in families of AD infants

Presented By
Dr Vesna Grivcheva-Panovska, University Clinic in Skopje (Macedonia)
Conference
EADV 2019

9 October, 2019 18:59

Statin use elevates risk of eczema and atopic dermatitis

Conference
WCD 2019

26 August, 2019 20:50

Insights into pathogenesis of AD define novel therapeutic targets

Presented By
Prof. Graham Ogg & Prof. Emma Guttman-Yassky
Conference
WCD 2019

26 August, 2019 20:29

Long awaited oral therapy for moderate-to-severe AD

Presented By
Prof. Thomas Bieber, University Medical Center Bonn, Germany
Conference
WCD 2019

26 August, 2019 19:14

Combinations are hot in AD treatment

Presented By
Dr Magdalena Trzeciak, Medical University of Gdansk, Poland
Trial
LIBERTY AD CHRONOS
Conference
WCD 2019

26 August, 2019 10:34

Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis

Presented By
Prof. Jonathan Barker, Kings College London, United Kingdom
Conference
SPIN 2019

21 June, 2019 20:34

Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis

Presented By
Prof. Peter van de Kerkhof, Radboud University Medical Center, the Netherlands
Conference
SPIN 2019

21 June, 2019 18:02

Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis

Presented By
Dr Nehal Mehta; Prof. Emma Guttman-Yassky
Trial
NHANES
Conference
SPIN 2019

21 June, 2019 14:38

Atopic dermatitis and psoriasis: on a spectrum?

Presented By
Prof. Emma Guttman-Yassky, Mount Sinai Medical School, USA
Conference
SPIN 2019

21 June, 2019 13:39

Bermekimab – a future treatment for atopic dermatitis?

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
Conference
AAD 2019

19 April, 2019 22:17

New and emerging atopic dermatitis therapies

Presented By
Prof. David Cohen, New York University School of Medicine, USA
Conference
AAD 2019

19 April, 2019 20:43

Tralokinumab improves eczema and reduces staphylococcus aureus colonisation in AD

Conference
AAD 2019

19 April, 2019 18:14

Can JAK inhibitors close the current therapeutic gap in AD?

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
Conference
AAD 2019

19 April, 2019 14:12

Food triggers eczema – an imperturbable belief of patients

Presented By
Dr Peter Lio, Northwestern University Chicago, USA
Conference
AAD 2019

19 April, 2019 13:45

AD sleep disturbance, antihistamines and osteoporosis

Presented By
Prof. Jonathan Silverberg, Northwestern University’s Feinberg School of Medicine, USA
Conference
AAD 2018

20 December, 2018 18:36

IL-17C inhibition in AD and new oral treatments

Presented By
Prof. Diamant Thaçi, University Clinic Schleswig-Holstein, Germany; Prof. Emma Guttmann-Yassky, Mount Sinai Hospital, USA
Conference
AAD 2018

20 December, 2018 17:20

New topical and systematic treatments

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
Conference
AAD 2018

20 December, 2018 16:42

Dual JAK/SYK inhibitor and anti-IL-33 blockade

Presented By
Dr Robert Bissonnette, Innovaderm Research, Canada; Prof. Graham Ogg, Oxford University, United Kingdom
Conference
AAD 2018

20 December, 2018 16:25

IL-4/IL-13 inhibition

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
Trial
SOLO
Conference
AAD 2018

20 December, 2018 11:49

[Long Read] Current Look on Asthma

Presented By
Prof. Zuzana Diamant, Skåne University Hospital Lund, Sweden; University Medical Center Groningen, the Netherlands
Trial
COSMEX, COSMOS, BORA
Conference
ERS 2018

7 November, 2018 23:25


Register to view our latest news directly from the conference and receive news notifications in your field.

Register Now
site created by:   

© 2023 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy